Navigation Links
GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
Date:5/12/2011

SAN DIEGO, May 12, 2011 /PRNewswire/ -- GT Life Sciences, Inc., (GT) a privately held biotechnology company announced today the issuance of Patent No. 7,856,317 for "SYSTEMS AND METHODS FOR CONSTRUCTING GENOMIC-BASED PHENOTYPIC MODELS" by the United States Patent and Trademark Office.  The '317 patent has a priority date of June 14, 2002 and contains broad, novel claims to computer systems and complex modeling processes by which scientists may use computational models to create scalable models to reconstruct biological networks and simulate biochemical functions.  GT holds an exclusive license to the '317 patent in the commercial life sciences field.

The '317 patent discloses and covers computational methods for constructing, simulating, and predicting the activity of metabolic network models where genes are linked to reactions.  Its claims cover systems and methods to create computational models of organisms for which genome-scale information is just now becoming available as well as to scale-up existing models to which new and additional genomic information can be added.  By using the inventions claimed in the '317 patent, scientists may significantly increase drug target identification and safety prediction in the drug discovery process, resulting in faster development of new drug therapies at greatly reduced cost.  

GT's intellectual property portfolio includes over 50 patents and patent applications, including portfolios licensed from Genomatica, the University of California and Penn State University. The issued and pending claims within GT's patent portfolio include constraint-based models as well as other modeling platforms focused on biological systems where genes, reactions and omics data can be represented, studied, and analyzed in an iterative process to enable and accelerate biological discovery. This intellectual property is at the heart of products derived from using genome-scale network reconstruction and model building, as well as model-driven data representation and computational analysis. Most, if not all, bottom-up metabolic systems biology is covered by GT's patent portfolio, with significant implications for all other cellular processes beyond metabolism. For example, the IP portfolio covers model reconstruction, high-throughput data mapping on network models, species-specific models (eg. human, mammalian cell lines, yeast and other microbial models).  GT's intellectual property conveys a vision of how systems biology would evolve, and the importance that in silico and high-throughput technologies can have on the maturation of this field. See (http://www.gtlifesciences.com/intellectual/patentestate.html).

"We believe that our patent portfolio represents one of the most valuable patent estates in the area of computational systems biology that enables genome-scale views of organism functions and their application to life science product discovery," stated Thomas Reed, President of GT Life Sciences.  "The '317 patent provides a strategic link with our existing portfolio of patents and patent applications owned and licensed in the field of computational biology.  Our licensees will now have a full tool box with which to accelerate product discovery and development. GT's technologies and patent portfolio address the growing importance of improving R&D efficiency and productivity in the pharmaceutical and life science industries."  

About GT Life Sciences, Inc.

GT Life Sciences (GT) is a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field. GT is a world leader in cellular metabolism, biochemical reactions, enzymatic transformations, networks and systems that control processes in cells. GT's platform is being applied to accelerate biological research, discovery and product development for both GT and its partners in a number of commercial opportunity areas in which cellular metabolism plays an important role. For more information, visit www.gtlifesciences.com.


'/>"/>
SOURCE GT Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, ... today on its R&D program in the use ... pulmonary disease (COPD). In June, 2015 InMed initiated ... to identify the targets and potential active compounds ... COPD. Subsequently, with in vitro assays using human ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
(Date:12/5/2016)... 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... presentation of preclinical and manufacturing data that support SB-525, its ... Annual Meeting of the American Society of Hematology (ASH) ... from December 3-6, 2016. "We have developed an ... we believe is highly competitive, and we remain on track ...
Breaking Medicine Technology:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:12/6/2016)... Georgia (PRWEB) , ... December 06, 2016 , ... ... consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry leading ... This prestigious, annual award recognizes USA as among the global elite in employer-sponsored ...
Breaking Medicine News(10 mins):